Monoclonal Antibodies and Cancer

  • Kewal K. Jain


A monoclonal antibody (MAb) is an antibody made from a single clone (hybridoma) of white blood cells. MAbs are used to block key receptors on tumor cell surfaces, compromising their function. MAbs may also be used to recruit the cellular arm of the immune system, planting a homing beacon on the transformed cell. MAbs, although produced in the laboratory, mimic the antibodies naturally produced by the body as part of immune system’s response to disease. The remarkable specificity of MAbs is also being harnessed in other ways, e.g., they are being paired with powerful toxins to create specific agents that seek out cancer cells and kill them. MAbs are also being employed for diagnosis, helping to identify the source of a tumor and provide a possibility for the treatment. MAbs enable the combination of diagnostics with therapeutics.


Epidermal Growth Factor Receptor Gemtuzumab Ozogamicin Bispecific Antibody Brentuximab Vedotin Tumor Cell Surface 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adair JR, Howard PW, Hartley JA, et al. Antibody-drug conjugates – a perfect synergy. Expert Opinion on Biological Therapy 2012;12:1191-206.CrossRefGoogle Scholar
  2. Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther 2012;12:251-7.CrossRefGoogle Scholar
  3. Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm 2013;70:589-97.CrossRefGoogle Scholar
  4. Gerber DE, Stopeck AT, Wong L, et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011;17:6888-96.CrossRefGoogle Scholar
  5. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087-98.Google Scholar
  6. Judy BF, Aliperti LA, Predina JD, et al. Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia 2012;14:352-9.Google Scholar
  7. Liddy N, Bossi G, Adams KJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012;18:980-7.CrossRefGoogle Scholar
  8. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-7.CrossRefGoogle Scholar
  9. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML. Antibody–cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther 2008;8:609-632.CrossRefGoogle Scholar
  10. Popkov M, Rader C, Gonzalez B, et al. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int J Cancer 2006;119:1194-207.CrossRefGoogle Scholar
  11. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012;17:954-63.CrossRefGoogle Scholar
  12. Royer B, Yin W, Pegram M, et al. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer 2010;102:827-32.CrossRefGoogle Scholar
  13. Sapra P, Hooper AT, O’Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Invest Drugs 2011;20:1131-49.CrossRefGoogle Scholar
  14. Scott AM, Gill SS, Lee F, et al. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 2006;Vol 24 Part I (Supplement 18S): Abstract No.13028.Google Scholar
  15. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012;12:14.Google Scholar
  16. Verma S, Miles D, Gianni L, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012;367:1783-91.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations